Element Biosciences vs Regeneron
Side-by-side comparison of AI visibility scores, market position, and capabilities
Element Biosciences makes the AVITI benchtop DNA sequencer; raised $277M Series D in 2024 (led by Wellington Management, Samsung) for $680M+ cumulative; install base grew from ~40 to 190+ units in 12 months.
About
Element Biosciences is a genomics company developing next-generation DNA sequencing instruments and reagents designed to democratize access to high-quality, cost-effective sequencing. Founded in 2017 by veterans from Illumina, Life Technologies, and other genomics leaders, the company is headquartered in San Diego, California. Its flagship product, the AVITI System, is a benchtop sequencer that combines high accuracy, flexible throughput, and competitive per-sample costs — making research-grade sequencing accessible to academic labs, biotech companies, agricultural research programs, and clinical settings that previously could not justify large capital outlays for sequencing infrastructure.
Tarrytown NY biopharma giant; creator of Dupixent (>$14B revenue), Eylea, and Kevzara. Velocity Genome platform drives fast antibody and bispecific drug discovery.
About
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized mouse technology that dramatically accelerates the discovery of human antibodies—and has used it to produce multiple best-in-class biologics across inflammatory, oncologic, and eye diseases.\n\nRegeneron's commercial portfolio is anchored by Dupixent (dupilumab), developed with Sanofi, which has become one of the best-selling drugs globally with over $14 billion in 2024 revenues, treating atopic dermatitis, asthma, COPD, and other type-2 inflammatory conditions. Additional key products include Eylea (aflibercept) for macular degeneration and PRALUENT for cardiovascular cholesterol lowering. The company's bispecific antibody pipeline, cancer vaccines in collaboration with BioNTech, and gene therapy programs represent its next growth wave.\n\nRegeneron reported over $14 billion in annual revenue in 2024 and maintains a world-class science culture, consistently ranking among the top companies for R&D productivity and employee satisfaction. Its Tarrytown campus houses more than 10,000 employees and remains a leading independent US biopharmaceutical innovator.
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.